Search:
Contact Us
Genomic Health
About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ¬ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ¬ Liquid Select» test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn. About Oncotype DX¬ The Oncotype DX¬ portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score¬, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score» predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score» predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.
Biotechnology
500 - 1,000
Redwood City, CA, United States
About

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ¬ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ¬ Liquid Select» test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX¬
The Oncotype DX¬ portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score¬, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score» predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score» predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Site Traffic
  • 893972 Global Rank
  • 177116
    United States
Traffic Sources
  • Search
    50.08%
  • Direct
    26.45%
  • Referrals
    23.27%
  • Mail
    0.19%
  • Display
    0.00%
  • Social
    0.00%
Powered by
Alexa Traffic Data
Global Rank 809,710
176
Links In Count 169
17
United States Rank 519,350
5
United States Page Views 45.9%
2.6%
Top Countries
Top Sites Linking In
Top Search Keywords
  • Lawyers and Law Firms
  • Business and Corporate Law
Mobile App Data
MixRank is the most comprehensive database of mobile apps, developers, SDKs, technologies, services, and integrations. Learn more.
  • 7 SDKs
  • App Url: https://itunes.apple.com/app/genomic-health/id1080833529
  • App Support: http://www.genomichealth.com
  • Genre: Medical
  • Bundle ID: com.genomichealth.ProstateCancerClinicalRiskClassificationTool
  • App Size: 27.3 M
  • Version: 2.1.0
  • Release Date: March 23rd, 2016
  • Update Date: August 16th, 2016

Description:

The Prostate Cancer Clinical Risk Classification app allows healthcare professionals to input clinical values to return a Prostate Cancer Risk Group Classification (Very Low, Low, Intermediate, High, Very High), based on the NCCN® Clinical Practice Guidelines Version 3.2016. You will answer up to 6 questions about your patient with localized (N0 M0) prostate cancer to generate an anonymous NCCN® Risk Group Classification. No patient information is stored locally or remotely.

Clinical parameters include:

* Gleason Score

* PSA Level

* Clinical T-Stage

* # of Positive Cores

* Total % tumor involvement in any core

* # cores with 4+3

* PSA Density

The result screen prominently displays the NCCN® Risk Group, as well as a summary of the values that were entered. The results will also indicate whether a patient with the entered clinical parameters would be eligible for the Oncotype DX® test. The Oncotype DX® Genomic Prostate Score is a biopsy-based gene expression test that predicts the biologic aggressiveness of disease in men with clinically low-risk prostate cancer. The Oncotype DX Genomic Prostate Score refines risk stratification, providing critical information for urologists and patients to confidently choose Active Surveillance or immediate treatment.

The Prostate Cancer Clinical Risk Classification app is supported by Genomic Health, Inc. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.3.2016.

For more information on the Oncotype DX® Genomic Prostate Score, visit www.oncotypedx.com.

Core Foundation Framework
Core Foundation is a framework that provides fundamental software services useful to application services, application environments, and to applications themselves. Core Foundation also provides abstractions for common data types, facilitates internationalization with Unicode string storage, and offers a suite of utilities such as plug-in support, XML property lists, URL resource access, and preferences.
Core Graphics
The Core Graphics framework is based on the Quartz advanced drawing engine. It provides low-level, lightweight 2D rendering with unmatched output fidelity. You use this framework to handle path-based drawing, transformations, color management, offscreen rendering, patterns, gradients and shadings, image data management, image creation, and image masking, as well as PDF document creation, display, and parsing.
Foundation Framework
The Foundation framework provides a base layer of functionality for apps and frameworks, including data storage and persistence, text processing, date and time calculations, sorting and filtering, and networking. The classes, protocols, and data types defined by Foundation are used throughout the macOS, iOS, watchOS, and tvOS SDKs.
Launch Services
macOS Launch Services is an API that enables a running app to open other apps or their document files, similar to the Finder or the Dock.Launch Services eliminates apps having to query the Finder to open an app, document, or URL for them. The macOS Finder itself uses Launch Services to perform such tasks. Because the Finder performs no additional processing beyond calling Launch Services, any client using Launch Services for these purposes behaves identically to the Finder.
Quartz Core Framework
Allow users to browse, edit, and save images, using slideshows and Core Image filters.The Quartz Composer API supports processing and rendering graphical data and allows developers to create custom patches for the Quartz Composer developer tool. ImageKit provides user interface support for browsing, editing, and saving images, showing slideshows, and browsing and previewing Core Image filters. PDFKit is a technology that allows applications to display and manipulate PDF documents.
UIKit
The UIKit framework (UIKit.framework) provides the crucial infrastructure needed to construct and manage iOS apps. This framework provides the window and view architecture needed to manage an app’s user interface, the event handling infrastructure needed to respond to user input, and the app model needed to drive the main run loop and interact with the system.
VoiceItApi2IosSDK
A library that gives you access to the VoiceIt's API 2.0 featuring Voice + Face Verification and Identification right in your iOS app.
Data sourced from MixRank, the most comprehensive database of mobile apps, developers, SDKs, technologies, services, and integrations. Learn More.
Ad Intelligence
  • Standard
    50.00%
  • Direct
    50.00%
Ads Seen Recently
1
Latest Publishers
Publisher Ranking
Longest Running Ad
Genomic Health
Device
Desktop
Dimensions
300x250
Dates Active
Aug 08, 2019 to Dec 14, 2019
Genomic Health
Device
Desktop
Dimensions
300x250
Dates Active
Aug 08, 2019 to Dec 14, 2019
They are headquartered at Redwood City, CA, United States, and have 6 advertising & marketing contacts listed on Kochava. Genomic Health works with Advertising technology companies such as The Trade Desk, Videology, DemDex, DoubleClick.Net, AOL-Time Warner Online Advertising, AppNexus, Turn, Atlas, Dstillery, Resonate Insights, BlueKai, Neustar AdAdvisor, Chango, AppNexus Segment Pixel, BlueKai DMP, ExactTarget.
Powered by Kochava
Alternatives & Competitors

Similar to Genomic Health

Genomic Health Alternatives & Competitors
Agendia is a leading molecular diagnostics company that develops an...
(1 contacts listed)
Clinical Genomics is a privately held biotechnology company develop...
(2 contacts listed)
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider ...
(4 contacts listed)
Veran is a privately held medical device company headquartered in S...
(2 contacts listed)
Celgene Corporation is an integrated global pharmaceutical company ...
(24 contacts listed)
More children die of brain tumors than any other cancer. The Pediat...
(2 contacts listed)
Biothera Pharmaceuticals is a privately held biotechnology company ...
(0 contacts listed)
Premaitha Health (AIM: NIPT) is an innovative molecular diagnostics...
(0 contacts listed)
Founded in 1907, the American Association for Cancer Research (AACR...
(5 contacts listed)
We are a biopharmaceutical company focused on acquiring, developing...
(4 contacts listed)
The National Association of Chronic Disease Directors (NACDD) is a ...
(2 contacts listed)
Entellus Medical is a medical technology company focused on deliver...
(3 contacts listed)
Quest Diagnostics (NYSE: DGX) empowers people to take action to imp...
(2 contacts listed)
The Mother's Day Classic (MDC) is an annual walk/run event held on ...
(0 contacts listed)
Meridian is a fully integrated life science company that develops, ...
(3 contacts listed)
Prometheus Laboratories Inc., A Nestle Health Science Company Abou...
(2 contacts listed)
The not-for-profit ADA is the nation's largest dental association, ...
(19 contacts listed)
BTG is a global specialist healthcare company bringing to market in...
(7 contacts listed)
Btg
BTG is a global specialist healthcare company bringing to market in...
(4 contacts listed)
Merck is a leading global biopharmaceutical company that has been i...
(0 contacts listed)
Recent Genomic Health Tweets
Recent Genomic Health Tweets
Last Updated 5/13/24
They are headquartered at Redwood City, CA, United States, and have 6 advertising & marketing contacts listed on Kochava. Genomic Health works with Advertising technology companies such as The Trade Desk, Videology, DemDex, DoubleClick.Net, AOL-Time Warner Online Advertising, AppNexus, Turn, Atlas, Dstillery, Resonate Insights, BlueKai, Neustar AdAdvisor, Chango, AppNexus Segment Pixel, BlueKai DMP, ExactTarget.